Lexicon Pharmaceuticals, Inc. (LXRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Lexicon Pharmaceuticals, Inc. (LXRX) is up 60.9% since the beginning of the year. At $2 per share, LXRX is trading 26.9% below its 52-week high of $3. Investors who bought $1,000 worth of LXRX shares 5 years ago would now be looking at an investment worth $417.

Lexicon Pharmaceuticals, Inc. (LXRX) has returned 60.87% so far this year and 192.72% over the past 12 months. Over the last ten years, LXRX has returned -18.68% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Apr 7, 2000, LXRX's average daily return is +0.08%, while the average monthly return is +1.35%. At this rate, an investment would double in approximately 4.3 years.

Historically, 47% of months were positive and 53% were negative. The best month was Jun 2000 with a return of +250.4%, while the worst month was Jul 2019 at -78.5%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, LXRX closed higher 46% of trading days. The best single day was Jan 14, 2021 with a return of +105.4%, while the worst single day was Jul 29, 2019 at -70.3%.

Lexicon Pharmaceuticals, Inc. has an annualized alpha of 9.51%, beta of 1.50, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since April 10, 2000.

• This stock participated in 182.92% of S&P 500 Index downside but only 115.15% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LXRX ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lexicon Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lexicon Pharmaceuticals, Inc. was 99.91%, occurring on Mar 3, 2025. The portfolio has not yet recovered.

The current Lexicon Pharmaceuticals, Inc. drawdown is 99.44%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lexicon Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lexicon Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.